Rochester, NY 9/2/2009 12:16:04 AM
CRXX CombinatoRx, Incorporated Up 18.26% on Good Volume
CRXX CombinatoRx, Incorporated
Last Trade: 1.75
Day's Range: 1.50 - 1.92
Volume: 1,563,752
Change: Up 0.2702 (18.26%)
CRXX CombinatoRx, Incorporated., a biopharmaceutical company, A subsidiary of Clinical Data Inc. and CombinatoRx Inc. have signed a licensing agreement valued at up to $257 million in milestone and royalty payments. The collaboration deal calls for Newton, Mass.-based Clinical Data (Nasdaq: CLDA) to license its multiple myeloma treatment, adenosine A2A agonist ATL313, to CombinatoRx. In return, Cambridge, Mass.-based CombinatoRx (Nasdaq: CRXX) will handle preclinical and clinical development of the treatment for B-cell malignancies. Clinical Data also can exercise a co-development option following Phase 2a study
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
About CRXX
CombinatoRx, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and outlicensing synergistic combination pharmaceuticals. It develops novel therapeutics with multi-target mechanisms of action that are built from combinations of drugs that utilize novel biology to treat various conditions, including immuno-inflammatory diseases, cancer, metabolic diseases, inherited diseases, and other diseases. The company?s products include Synavive, a novel dissociated glucocorticoid product candidate to enhance the anti-inflammatory benefits of glucocorticoids, which completed phase II in rheumatoid arthritis, knee osteoarthritis, hand osteoarthritis, and biomarker study; CRx-401, an anti-diabetic agent, which is in phase IIa clinical study; and CRx-191, a topical synergistic combination drug candidate that has completed phase IIa clinical trials for psoriasis. Its products also include CRx-197, a novel topical anti-inflammatory product candidate that completed phase IIa clinical trials for the treatment of psoriasis, atopic dermatitis, and other inflammatory dermatoses; and CRx-170, an oral synergistic combination drug candidate, which completed phase IIa clinical trial for the potential treatment of chronic pain conditions. The company has a collaboration and licensing agreement with Clinical Data Inc. to develop an adenosine A2A agonist compound in a combination therapy for the treatment of multiple myeloma, and other B-cell cancers. CombinatoRx, Incorporated also has collaborations with Angiotech Pharmaceuticals, Inc.; Fovea Pharmaceuticals SA; Cystic Fibrosis Foundation Therapeutics Incorporated; CHDI, Inc.; Charley?s Fund and the Nash Avery Foundation; National Institutes of Allergy and Infectious Diseases; HenKan Pharmaceutical Company; Spinal Muscular Atrophy Foundation; Sirtris Pharmaceuticals, Inc.; and Novartis AG. The company was founded in 2000 and is based in Cambridge, Massachusetts.
About StockEinstein
StockEinstein.com uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
This service is free and available only to subscribers. Scroll down this page or visit our site to join our free newsletter and begin receiving daily stock alerts.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
